Peter M A Calverley

Summary

Affiliation: University of Liverpool
Country: UK

Publications

  1. doi request reprint Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
    Peter M A Calverley
    School of Clinical Sciences, Liverpool, UK
    Lancet 374:685-94. 2009
  2. doi request reprint Current drug treatment, chronic and acute
    Peter Calverley
    Respiratory Research, Clinical Sciences Department, Institute of Ageing and Chronic Diseases, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, UK Electronic address
    Clin Chest Med 35:177-89. 2014
  3. doi request reprint Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations
    Peter Ma Calverley
    School of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK Aintree Chest Centre, University Hospital Aintree, Liverpool, UK Electronic address
    Lancet Respir Med 1:564-73. 2013
  4. pmc Factors associated with change in exacerbation frequency in COPD
    Gavin C Donaldson
    Centre for Respiratory Medicine, UCL Medical School, Royal Free Campus, Rowland Hill Street Hampstead, London NW3 2PF, UK
    Respir Res 14:79. 2013
  5. pmc The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale
    Robert A Wise
    Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA
    Respir Res 14:40. 2013
  6. pmc Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol
    Peter M A Calverley
    Clinical Science Center, University Hospital Aintree, Liverpool, United Kingdom
    Int J Chron Obstruct Pulmon Dis 7:375-82. 2012
  7. doi request reprint Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease
    Paul Albert
    School of Ageing and Chronic Disease, University Hospital Aintree, Lower Lane, Liverpool, UK
    Thorax 67:701-8. 2012
  8. pmc Health status in the TORCH study of COPD: treatment efficacy and other determinants of change
    Paul W Jones
    Department of Cardiac and Vascular Sciences, St George s Hospital, University of London, London, UK
    Respir Res 12:71. 2011
  9. pmc Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD
    Stephen I Rennard
    Nebraska Medical Center, Omaha, Nebraska, USA
    Respir Res 12:18. 2011
  10. pmc Characterisation of COPD heterogeneity in the ECLIPSE cohort
    Alvar Agusti
    Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Spain
    Respir Res 11:122. 2010

Detail Information

Publications41

  1. doi request reprint Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
    Peter M A Calverley
    School of Clinical Sciences, Liverpool, UK
    Lancet 374:685-94. 2009
    ..We therefore investigated whether roflumilast would reduce the frequency of exacerbations requiring corticosteroids in patients with COPD...
  2. doi request reprint Current drug treatment, chronic and acute
    Peter Calverley
    Respiratory Research, Clinical Sciences Department, Institute of Ageing and Chronic Diseases, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, UK Electronic address
    Clin Chest Med 35:177-89. 2014
    ..This article reviews the key components of the pharmacologic treatment of COPD, both acute and chronic, with an emphasis on those recent studies, which are likely to change practice in the next few years. ..
  3. doi request reprint Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations
    Peter Ma Calverley
    School of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK Aintree Chest Centre, University Hospital Aintree, Liverpool, UK Electronic address
    Lancet Respir Med 1:564-73. 2013
    ..In this Review we will discuss the insight that studies of bronchodilator reversibility have provided into the nature of the COPD, and how the abnormal physiology seen in patients with this disorder can be interpreted. ..
  4. pmc Factors associated with change in exacerbation frequency in COPD
    Gavin C Donaldson
    Centre for Respiratory Medicine, UCL Medical School, Royal Free Campus, Rowland Hill Street Hampstead, London NW3 2PF, UK
    Respir Res 14:79. 2013
    ..Although most patients do not change category from year to year, some will, and the factors associated with this behaviour have not been examined...
  5. pmc The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale
    Robert A Wise
    Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA
    Respir Res 14:40. 2013
    ..Comparing across programs tiotropium Respimat Soft Mist inhaler was at least as efficacious as tiotropium HandiHaler, however, concerns have been raised about tiotropium's safety when given via Respimat...
  6. pmc Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol
    Peter M A Calverley
    Clinical Science Center, University Hospital Aintree, Liverpool, United Kingdom
    Int J Chron Obstruct Pulmon Dis 7:375-82. 2012
    ..Roflumilast is approved to treat severe COPD in patients with chronic bronchitis--and a history of frequent exacerbations--as an add-on to bronchodilators...
  7. doi request reprint Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease
    Paul Albert
    School of Ageing and Chronic Disease, University Hospital Aintree, Lower Lane, Liverpool, UK
    Thorax 67:701-8. 2012
    ..We studied whether change in lung function after a bronchodilator is abnormal in COPD, whether stable responder subgroups can be identified, and whether these subgroups experience different clinical outcomes...
  8. pmc Health status in the TORCH study of COPD: treatment efficacy and other determinants of change
    Paul W Jones
    Department of Cardiac and Vascular Sciences, St George s Hospital, University of London, London, UK
    Respir Res 12:71. 2011
    ..Little is known about factors that determine health status decline in clinical trials of COPD...
  9. pmc Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD
    Stephen I Rennard
    Nebraska Medical Center, Omaha, Nebraska, USA
    Respir Res 12:18. 2011
    ..This led to the question of whether a responsive subset existed that could be investigated further...
  10. pmc Characterisation of COPD heterogeneity in the ECLIPSE cohort
    Alvar Agusti
    Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Spain
    Respir Res 11:122. 2010
    ..Chronic obstructive pulmonary disease (COPD) is a complex condition with pulmonary and extra-pulmonary manifestations. This study describes the heterogeneity of COPD in a large and well characterised and controlled COPD cohort (ECLIPSE)...
  11. ncbi request reprint Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease
    P M Calverley
    Dept of Medicine, Clinical Sciences, University Hospital Aintree, Liverpool, UK
    Eur Respir J 22:912-9. 2003
    ..Budesonide/formoterol in a single inhaler (Symbicort) maintains the benefit of treatment optimisation, stabilising lung function and delaying exacerbations more effectively than either component drug alone or placebo...
  12. pmc COPD: what is the unmet need?
    P M A Calverley
    School of Clinical Sciences, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Br J Pharmacol 155:487-93. 2008
    ..Defining subsets of patients responsive to more specific interventions is the major challenge for the next decade in this field...
  13. pmc One-year treatment with mometasone furoate in chronic obstructive pulmonary disease
    Peter M A Calverley
    Department of Medicine, University Hospital Aintree, Liverpool, UK
    Respir Res 9:73. 2008
    ..031). MF-DPI treatment was well tolerated.Once-daily MF-DPI improved lung function and health status in subjects with moderate-to-severe COPD and was comparable to BID MF-DPI...
  14. doi request reprint Reported pneumonia in patients with COPD: findings from the INSPIRE study
    Peter M A Calverley
    Clinical Science Centre, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, England
    Chest 139:505-12. 2011
    ..We investigated patient characteristics and symptoms occurring before pneumonia reports in the Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) study...
  15. doi request reprint Cardiovascular events in patients with COPD: TORCH study results
    Peter M A Calverley
    Department of Medicine, University Hospital Aintree, Longmoor Lane, Liverpool, UK
    Thorax 65:719-25. 2010
    ....
  16. doi request reprint Beclomethasone/formoterol in the management of COPD: a randomised controlled trial
    P M A Calverley
    Pulmonary and Rehabilitation Research Group, Dept of Medicine, Clinical Sciences, University Hospital Aintree, Longmoor Lane, Liverpool, United Kingdom
    Respir Med 104:1858-68. 2010
    ..To evaluate the effect of beclomethasone/formoterol versus budesonide/formoterol (non-inferiority) and versus formoterol (superiority) in patients with severe stable chronic obstructive pulmonary disease (COPD)...
  17. pmc The severity of airways obstruction as a determinant of treatment response in COPD
    Peter Calverley
    Clinical Research Centre, University Hospital Aintree, Liverpool, UK
    Int J Chron Obstruct Pulmon Dis 1:209-18. 2006
    ....
  18. ncbi request reprint What have we learned from large drug treatment trials in COPD?
    Peter M A Calverley
    Division of Infection and Immunity, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Lancet 370:774-85. 2007
    ..Ensuring that these expensive studies are done objectively to the highest standard is an important goal for the next decade...
  19. ncbi request reprint Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
    Peter M A Calverley
    Department of Medicine, Clinical Sciences, University Hospital Aintree, Liverpool L97AL, UK
    Am J Respir Crit Care Med 176:154-61. 2007
    ..Whether treatment is effective in more severe COPD (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stages III and IV) over a longer period is unknown...
  20. ncbi request reprint Relationship between respiratory symptoms and medical treatment in exacerbations of COPD
    P Calverley
    The University Hospital Aintree, Liverpool Longmoor Lane, L9 7AL, UK
    Eur Respir J 26:406-13. 2005
    ..However, daily symptom monitoring is too variable using the current diary cards to make individual management decisions...
  21. ncbi request reprint Effect of corticosteroids on exacerbations of asthma and chronic obstructive pulmonary disease
    Peter M A Calverley
    Department of Medicine, University Hospital Aintree, Clinical Sciences Centre, Longmoor Lane, Liverpool L9 7AL, UK
    Proc Am Thorac Soc 1:161-6. 2004
    ..However, given the impact of exacerbations on overall quality of life in COPD, even this modest reduction is likely to be clinically important...
  22. ncbi request reprint Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease
    Peter M A Calverley
    Department of Medicine, University Hospital Aintree, Clinical Sciences Centre, Longmoor Lane, Liverpool L9 7AL, UK
    Proc Am Thorac Soc 1:121-4. 2004
    ..Health status changes mirrored these effects. In summary, combination therapy can effectively prevent exacerbations in patients with more advanced COPD...
  23. ncbi request reprint The role of corticosteroids in chronic obstructive pulmonary disease
    Peter M A Calverley
    Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool L9 7AL, United Kingdom
    Semin Respir Crit Care Med 26:235-45. 2005
    ..Inhaled corticosteroids are not suitable for monotherapy in COPD but can be helpfully combined with an inhaled bronchodilator in patients with symptomatic disease...
  24. ncbi request reprint Withdrawal from treatment as an outcome in the ISOLDE study of COPD
    Peter M A Calverley
    Department of Medicine, University Hospital Aintree, Liverpool, United Kingdom
    Chest 124:1350-6. 2003
    ..To investigate the determinants of patient withdrawal from our study, and the effect of these withdrawals on the outcome of treatment with inhaled corticosteroids in patients with COPD...
  25. pmc Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease
    P M A Calverley
    Department of Medicine, University of Liverpool, Liverpool, UK
    Thorax 58:855-60. 2003
    ..We hypothesised that tiotropium would modify the overnight change in FEV1, and this would be unaffected by the timing of drug administration...
  26. pmc Bronchodilator reversibility testing in chronic obstructive pulmonary disease
    P M A Calverley
    Department of Medicine, The University of Liverpool, Liverpool, UK
    Thorax 58:659-64. 2003
    ..The reliability of the recommended response criteria and their relationship to disease progression has not been established...
  27. ncbi request reprint Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
    Peter Calverley
    Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Lancet 361:449-56. 2003
    ..We postulated that a combination of these treatments would be better than each component used alone...
  28. ncbi request reprint Conclusion. Lessons from the novel D2 dopamine receptor, beta2-adrenoceptor agonist, Viozan: chronic obstructive pulmonary disease and drug development implications
    P Calverley
    University Department of Medicine, University Hospital Aintree, Liverpool, UK
    Respir Med 97:S71-4. 2003
    ..Subsequent clinical assessment has amassed a wealth of data from over 4000 patients, providing valuable insights into COPD, clinical trial design and the value of patient self-assessment tools...
  29. ncbi request reprint Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events?
    Peter M A Calverley
    Clinical Science Centre, University Hospital Aintree, Liverpool, UK
    COPD 3:233-42. 2006
    ..A large multicenter prospective randomized trial (Towards a Revolution in COPD Health [TORCH]) is now ongoing and will examine the effect of fluticasone propionate in combination with salmeterol on all-cause mortality...
  30. ncbi request reprint Development of a population-based screening questionnaire for COPD
    Peter M A Calverley
    University of Liverpool, Liverpool, L9 7AL, UK
    COPD 2:225-32. 2005
    ..Dissemination of such tools should raise awareness among at-risk persons and help identify COPD patients in the primary care setting...
  31. ncbi request reprint Minimal clinically important difference--exacerbations of COPD
    Peter M A Calverley
    Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    COPD 2:143-8. 2005
    ..Existing methodologies for estimating clinically important differences are hard to apply with a binary outcome like this, and more work will be needed to develop a robust approach for dealing with this important clinical variable...
  32. ncbi request reprint Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Peter M A Calverley
    University Hospital Aintree, Liverpool, United Kingdom
    N Engl J Med 356:775-89. 2007
    ..Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown...
  33. pmc Chronic airflow limitation in a rural Indian population: etiology and relationship to body mass index
    Biswajit Chakrabarti
    Aintree Chest Centre, University Hospital Aintree, Liverpool, UK
    Int J Chron Obstruct Pulmon Dis 6:543-9. 2011
    ..As such, this study aimed to explore factors associated with the development of airflow obstruction (AFO) in a rural Indian setting and, using spirometry, study whether underweight is linked to AFO...
  34. doi request reprint The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease
    Paul P Walker
    Division of Infection and Immunity, School of Clinical Sciences, University of Liverpool, Liverpool, United Kingdom
    COPD 5:147-52. 2008
    ..We suggest that post-bronchodilator absolute change in FVC provides important additional physiological information when interpreting bronchodilator reversibility testing...
  35. doi request reprint Lung function changes following methacholine inhalation in COPD
    Paul P Walker
    Division of Infection and Immunity, School of Clinical Sciences, University of Liverpool, University Hospital Aintree, Liverpool, UK
    Respir Med 103:535-41. 2009
    ....
  36. doi request reprint Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease
    Bipen D Patel
    Department of Medicine, University of Cambridge, Cambridge, UK
    Am J Respir Crit Care Med 178:500-5. 2008
    ..It is unclear whether airway wall thickening and emphysema make independent contributions to airflow limitation in chronic obstructive pulmonary disease (COPD) and whether these phenotypes cluster within families...
  37. ncbi request reprint Dynamic hyperinflation: is it worth measuring?
    Peter M A Calverley
    School of Clinical Sciences, University Hospital Aintree, Liverpool, UK
    Proc Am Thorac Soc 3:239-44. 2006
    ....
  38. ncbi request reprint Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease
    Nicola J Stevenson
    Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK
    Am J Respir Crit Care Med 172:1510-6. 2005
    ..Exacerbation of chronic obstructive pulmonary disease commonly causes hospitalization. The change in lung mechanics during exacerbation and its relationship to symptoms in spontaneously breathing individuals has not been described...
  39. doi request reprint A study of patient attitudes in the United Kingdom toward ventilatory support in chronic obstructive pulmonary disease
    Biswajit Chakrabarti
    Clinical Sciences Centre, University of Liverpool, University Hospital Aintree, Liverpool, United Kingdom
    J Palliat Med 12:1029-35. 2009
    ....
  40. pmc Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease
    Biswajit Chakrabarti
    Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Int J Chron Obstruct Pulmon Dis 2:263-72. 2007
    ..Patients diagnosed with TB may often have extensive co-morbidity such as COPD and the effect of an underlying diagnosis of COPD on outcomes in TB is also reviewed...
  41. doi request reprint The evidence for the use of oral mucolytic agents in chronic obstructive pulmonary disease (COPD)
    L Davies
    Aintree Chest Centre, University Hospital Aintree, Lower Lane, Liverpool, UK
    Br Med Bull 93:217-27. 2010
    ..Oral mucolytics are now recommended in some treatment guidelines for the management of chronic obstructive pulmonary disease (COPD). This article reviews the evidence for their use and their possible benefits...